{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fharvard-thinking.simplecast.com%2Fepisodes%2Fglp-1s-DDfo17AG","width":444,"version":"1.0","type":"rich","title":"Who should take GLP-1s?","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/4e7f56d4-eb27-4ac4-9d9f-899ce9b93b68/f986d52c-c815-4bfd-92ae-a3fd718956ac/2023-11-28-gazette-ht-podcast-thumbnail-1.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/bd58d117-c3d2-4962-a149-fac536440c5b\" height=\"200\" width=\"100%\" title=\"Who should take GLP-1s?\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"GLP-1 usage has surged as a weight loss management drug. But given how new they are to the market, medical professionals are only now starting to figure out who should – and should not – be using them. In this episode, host Samantha Laine Perfas talks with obesity specialist Caroline Apovian, evolutionary biologist Daniel Lieberman, and obesity medicine physician scientist Fatima Cody Stanford about why we should be excited – and cautious – about the potential of GLP-1s."}